Regeneron Pharmaceuticals, Inc DEFA14A, filed Apr 23, 2021
Regeneron Pharmaceuticals, Inc. (REGN)
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
| o | Preliminary Proxy Statement |
| o | Soliciting Material Under Rule 14a-12 |
| o |
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| o | Definitive Proxy Statement |
| x | Definitive Additional Materials |
Regeneron Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. | |
| o | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |
| 1) | Title of each class of securities to which transaction applies:
| |
| 2) |
Aggregate number of securities to which transaction applies:
| |
| 3) |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
| |
| 4) |
Proposed maximum aggregate value of transaction:
| |
| 5) |
Total fee paid:
| |
| o | Fee paid previously with preliminary materials: | |
| o | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. | |
| 1) |
Amount previously paid:
| |
| 2) |
Form, Schedule or Registration Statement No.:
| |
| 3) | Filing Party:
| |
| 4) | Dated Filed:
| |
| Your Vote Counts!
REGENERON PHARMACEUTICALS, INC.
2021 Annual Meeting |
|||||
REGENERON PHARMACEUTICALS, INC. |
 |
||||
D51959-P48765-Z78980 |
|||||
You invested in REGENERON PHARMACEUTICALS, INC. and it’s time to vote!
You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 11, 2021.
Get informed before you vote
View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.
 |
For complete information and to vote, visit www.ProxyVote.com |
Control
#  |
Smartphone users
Point
your camera here and
|
 |
Vote Virtually at the Meeting*
June 11, 2021 | ||
|
Virtually at: www.virtualshareholdermeeting.com/REGN2021 | |||
| * | Please check the meeting materials for any special requirements for meeting attendance. | V1 |
Vote at www.ProxyVote.com
THIS IS NOT A VOTABLE BALLOT
This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote on these important matters.
| Voting Items | Board Recommends | |||
| 1. | Election of Directors | |||
| Nominees: | ||||
| 1a. | N. Anthony Coles, M.D. |  For | ||
| 1b. | Arthur F. Ryan | For | ||
| 1c. | George L. Sing | For | ||
| 1d. | Marc Tessier-Lavigne, Ph.D. | For | ||
| 2. | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. | For | ||
| NOTE: Such other business as may properly come before the meeting or any adjournment thereof. | ||||
| Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”. |
D51960-P48765-Z78980